<scp>LINC</scp>00511 interacts with miR‐765 and modulates tongue squamous cell carcinoma progression by targeting <scp>LAMC</scp>2

Ding, Junhai; Yang, Changxi; Yang, Sen

doi:10.1111/jop.12677

Cited by 68 publications

(67 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overexpression of LINC00511 in TSCC has been reported in two independent array studies analysing tissues from 46 patients (Ding, Yang, & Yang, ; Ye et al., ), while the underexpression of C14orf132, C17orf76‐AS1, EPB41L4A‐AS1, LINC00341, OTTHUM00000159695 and the overexpression of LINC00094, LINC00520, SNHG15/SNORA9 have been reported in one microarray study (Ye et al., ). Of note, the same differential expressions were previously reported in a microarray study investigating a mixed cohort of oral and oropharyngeal SCCs, where data from OSCCs cannot be separated (Chen et al., ).…”

Section: Introductionmentioning

confidence: 88%

World Workshop on Oral Medicine VII: Clinical evidence of differential expression of lncRNAs in oral squamous cell carcinoma: A scoping review

et al. 2019

View full text Add to dashboard Cite

Background Long non‐coding RNAs (lncRNAs) have important roles in regulating gene expression pertaining to cell proliferation, survival, migration and genomic stability. Dysregulated expression of lncRNAs is implicated in cancer initiation, progression and metastasis. Objectives To explore, map and summarize the extent of evidence from clinical studies investigating the differential expression of lncRNAs in oral/tongue squamous cell carcinoma. Methods PubMed, Scopus and Web of Science were used as search engines. Clinical, full‐length, English language studies were included. PRISMA‐ScR protocol was used to evaluate and present results. The present scoping review summarizes relationships of the differential expression of lncRNAs with the presence of tumour and with clinicopathological features including survival. Results Almost half of the investigated transcripts have been explored in more than one study, yet not always with consistent results. The collected data were also compared to the limited studies investigating oral epithelial dysplasia. Data are not easily comparable, first because of different methods used to define what differential expression is, and second because only a limited number of studies performed multivariate analyses to identify clinicopathological features associated with the differentially expressed lncRNAs. Conclusions Standard methods and more appropriate data analyses are needed in order to achieve reliable results from future studies.

show abstract

Section: Introductionmentioning

confidence: 88%

World Workshop on Oral Medicine VII: Clinical evidence of differential expression of lncRNAs in oral squamous cell carcinoma: A scoping review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Growing evidence suggested that lncRNAs were deregulated in many tumors such as bladder cancer, gallbladder cancer, hepatocellular carcinoma (HCC), lung cancer, glioma, and osteosarcoma . Recently, a new LncRNA Linc00511 was shown to be deregulated in some tumors such as breast cancer, non–small‐cell lung cancer, pancreatic ductal adenocarcinoma (PDAC), and tongue squamous cell carcinoma (TSCC) . Linc00511 has been identified in these cancers to function as oncogenes .…”

Section: Introductionmentioning

confidence: 99%

“…[22][23][24][25][26][27][28] Recently, a new LncRNA Linc00511 was shown to be deregulated in some tumors such as breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma (PDAC), and tongue squamous cell carcinoma (TSCC). [29][30][31][32] Linc00511 has been identified in these cancers to function as oncogenes. 31,32 However, to our knowledge, there are no studies on the functional role of Linc00511 in osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

LncRNA Linc00511 promotes osteosarcoma cell proliferation and migration through sponging miR‐765

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Long noncoding RNA (lncRNA) Linc00511 is a novel lncRNA, and it was reported to play important roles in the progression and carcinogenesis of several tumors. However, the expression and biological roles of Linc00511 in osteosarcoma were still unknown. In this research, we showed that the expression of Linc00511 was upregulated in osteosarcoma samples and cell lines. Ectopic expression of Linc00511 promoted osteosarcoma cell growth, colony formation, and migration. Moreover, overexpression of Linc00511 enhanced the epithelial‐mesenchymal transition progression in osteosarcoma cell. In addition, we showed that elevated expression of Linc00511 suppressed microRNA‐765 (miR‐765) expression and promoted apurinic/apyrimidinic endonuclease 1 (APE1) expression in osteosarcoma cell. The expression of miR‐765 was downregulated in osteosarcoma cells and samples and was negatively related to Linc00511 expression in osteosarcoma tissues. Ectopic expression of miR‐765 inhibited osteosarcoma cell growth and migration. Furthermore, we showed that Linc00511 overexpression promoted MG‐63 cells proliferation, colony formation, and migration via downregulation of miR‐765. These results suggested that Linc00511 played as an oncogene in the development of osteosarcoma.

show abstract

“…The functional role of LINC00511 in BC is not yet understood, however, this lncRNA acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing P57 105. and as ceRNA in pancreatic ductal adenocarcinoma106 and in tongue squamous carcinoma 107. MEG3, LINC00152, DANCR and MALAT1 are associated with ER-positive and TNBC subtypes (Figure 2).…”

mentioning

confidence: 99%

Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?

et al. 2019

View full text Add to dashboard Cite

Breast Cancer (BC) is the most commonly diagnosed cancer and is the leading cause of cancer deaths in women. BC is a heterogeneous disease with different clinical and genetic features. According to immunohistochemical markers, BC is subdivided into four main subtypes: luminal A, luminal B, ERBB2 positive and triple negative. Long non‐coding RNAs (lncRNAs) are transcripts with more than 200 nucleotides and deregulated lncRNAs are associated with human diseases, including BC. In order to improve BC molecular classification, non‐coding RNAs (ncRNAs), including lncRNAs, have been used. In this review, we focus on lncRNAs with differential expression in BC subtypes and how these RNAs may act to contribute to BC heterogeneity. We also emphasize the potential of these lncRNAs as biomarkers.

show abstract

LINC00511 interacts with miR‐765 and modulates tongue squamous cell carcinoma progression by targeting LAMC2

Cited by 68 publications

References 23 publications

World Workshop on Oral Medicine VII: Clinical evidence of differential expression of lncRNAs in oral squamous cell carcinoma: A scoping review

World Workshop on Oral Medicine VII: Clinical evidence of differential expression of lncRNAs in oral squamous cell carcinoma: A scoping review

LncRNA Linc00511 promotes osteosarcoma cell proliferation and migration through sponging miR‐765

Long non‐coding RNAs differential expression in breast cancer subtypes: What do we know?

Contact Info

Product

Resources

About